FDA grants accelerated approval to Eteplirsen, first drug for Duchenne muscular dystrophy
Posted on23 Sep 2016
TagsDuchenne muscular dystrophy, Eteplirsen, Fast Track designation, orphan drug, orphan drug designation, priority review
Comments0
The U.S. Food and Drug Administration today approved Exondys 51 (eteplirsen) injection, the first drug approved to treat patients with Duchenne muscular... Read More